Today's successful businesses operate with a lean, permanent core surrounded by a dynamic, on-demand layer of world-class ...

SINGAPORE & OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) will present data from two global Phase 3 double-blind, placebo-controlled studies of oveporexton (TAK-861) 1, ...

The poster presentation can be found on Alterity’s website here.

HONG KONG, Sept. 9, 2025 /PRNewswire/ -- Akeso Inc. (9926.HK) announced that data from a Phase Ib/II clinical study evaluating the combination of cadonilimab and pulocimab (an anti-VEGFR-2 antibody) ...

Takeda (TSE:4502/NYSE:TAK) will present data from two global Phase 3 double-blind, placebo-controlled studies of oveporexton (TAK-861) 1, a potential first-in-class investigational oral orexin ...

Impact on the 12 core human capacities will be more negatively than positively in the next 10 years, says more than half of ...

LYON, France, September 03, 2025--(BUSINESS WIRE)--Regulatory News: Adocia (Euronext Paris: FR0011184241 – ADOC, the "Company"), a clinical-stage biopharmaceutical company focused on the research and ...

Ondine Biomedical Inc. (LON: OBI) announces that it was invited to make an oral presentation about health and economic benefits of Steriwave nasal photodisinfection at the 12th International ...

During year 6 of continuous treatment with BRIUMVI the annualized relapse rate was 0.012, equivalent to one relapse occurring every 83 years of ...

WILMETTE, Ill., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar” or the "Company”) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative ...

The iX3 is likely to be one of the new automotive releases of the year that will attract a lot of attention. BMW, already the most successful German premium brand in the electromobility sector, wants ...